Saltar al contenido
Merck

The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.

Journal of virology (2003-05-14)
Ralph A Tripp, Azzeddine Dakhama, Les P Jones, Albert Barskey, Erwin W Gelfand, Larry J Anderson
RESUMEN

Respiratory syncytial virus (RSV) infection in the neonate can alter respiratory rates, i.e., lead to episodes of apnea. We show that RSV G glycoprotein reduces respiratory rates associated with the induction of substance P (SP) and G glycoprotein-CX3CR1 interaction, an effect that is inhibited by treatment with anti-G glycoprotein, anti-SP, or anti-CX3CR1 monoclonal antibodies. These data suggest new approaches for treating some aspects of RSV disease.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-VRS, proteína de fusión, todas las cepas tipo s A, B, clon 131-2A, clone 131-2A, Chemicon®, from mouse